SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Biotechnology Act Europe Driving Innovation and Investment in Life Sciences
The Biotechnology Act Europe offers a once-in-a-generation chance to turn the continent’s world-class life sciences research into scalable commercial successes that remain in Europe rather than migrating elsewhere. By tackling regulatory fragmentation and sharpening investment signals, the legisl...
Rising Trends in Early-Onset Colorectal Cancer Burden
Early-onset colorectal cancer is rising sharply among adults under 50, even as overall colorectal cancer incidence and mortality have declined through improved prevention and treatment. Contemporary adults aged 30 to 40 now face higher risks at younger ages than their grandparents did, with the d...
Pioneering AI PICO Scoping Tool Enhances EU Joint Clinical Assessments
A recently published AI PICO Scoping Tool delivers a practical solution for the demanding requirements of EU Joint Clinical Assessments by automatically extracting and consolidating Population, Intervention, Comparator, and Outcome (PICO) elements from disparate health technology assessment repor...